Blab Business
Eli Lilly Boosts Q1 2026 Earnings, Expands into Vaccines with $3.8 B Acquisition
Eli Lilly and Company (NYSE: LLY) announced its first‑quarter 2026 results on April 30, 2026. Worldwide revenue rose 56 % to $19.8 billion, driven largely by the company’s two flagship glucagon‑like peptide‑1 (GLP‑1) drugs, Mounjaro and Zepbound. Net income increased 168 % to $7.4 billion, and earnings per share were $8.55, well above the $6.97 consensus estimate.
Mounjaro and Zepbound together generated roughly $12.8 billion of the $19.8 billion in revenue. According to the company’s earnings release, sales of Mounjaro grew 125 % year‑over‑year and Zepbound sales grew 80 % in the same period. Both drugs are GLP‑1 receptor agonists that treat type 2 diabetes and obesity; Lilly is the current market leader in the GLP‑1 category. The company’s price‑to‑earnings ratio stands at 39×, higher than the average for the pharmaceutical sector, which is about 24×.
On May 27, 2026, Lilly disclosed plans to acquire three vaccine developers—Curevo, LimmaTech Biologics AG, and a third company—at a combined purchase price of $3.8 billion. The acquisitions are intended to broaden Lilly’s presence in the infectious‑disease space. According to a press release from Lilly, the new vaccine assets will complement the company’s existing oncology and inflammatory‑disease programs.
The move into vaccines is described by Lilly executives as a long‑term diversification strategy. The company’s leadership has noted that the GLP‑1 drugs, while currently driving strong revenue, are subject to patent expirations that will eventually erode market share. By investing in vaccine development, Lilly seeks to build a more resilient portfolio that can sustain growth once the GLP‑1 patent life ends.
Investors who focus on growth are likely to view the vaccine acquisitions favorably, as they signal Lilly’s intent to expand beyond its current therapeutic focus. The company’s Q1 earnings report also highlighted a pipeline of additional GLP‑1 candidates, including a newly released pill named Foundayo, which could further extend Lilly’s leadership in the obesity market.
In the near term, analysts will monitor the performance of Mounjaro and Zepbound, the progress of Lilly’s vaccine projects, and the company’s guidance for the remainder of 2026. Lilly’s next earnings call is scheduled for July 15, 2026, where it is expected to provide updated revenue forecasts and discuss the integration of the newly acquired vaccine assets.
Overall, Eli Lilly’s Q1 2026 results confirm the strength of its GLP‑1 portfolio while illustrating a strategic pivot toward infectious‑disease vaccines. The company’s current financial performance, coupled with its planned acquisitions, positions it to address both short‑term profitability and long‑term diversification.
Mounjaro and Zepbound together generated roughly $12.8 billion of the $19.8 billion in revenue. According to the company’s earnings release, sales of Mounjaro grew 125 % year‑over‑year and Zepbound sales grew 80 % in the same period. Both drugs are GLP‑1 receptor agonists that treat type 2 diabetes and obesity; Lilly is the current market leader in the GLP‑1 category. The company’s price‑to‑earnings ratio stands at 39×, higher than the average for the pharmaceutical sector, which is about 24×.
On May 27, 2026, Lilly disclosed plans to acquire three vaccine developers—Curevo, LimmaTech Biologics AG, and a third company—at a combined purchase price of $3.8 billion. The acquisitions are intended to broaden Lilly’s presence in the infectious‑disease space. According to a press release from Lilly, the new vaccine assets will complement the company’s existing oncology and inflammatory‑disease programs.
The move into vaccines is described by Lilly executives as a long‑term diversification strategy. The company’s leadership has noted that the GLP‑1 drugs, while currently driving strong revenue, are subject to patent expirations that will eventually erode market share. By investing in vaccine development, Lilly seeks to build a more resilient portfolio that can sustain growth once the GLP‑1 patent life ends.
Investors who focus on growth are likely to view the vaccine acquisitions favorably, as they signal Lilly’s intent to expand beyond its current therapeutic focus. The company’s Q1 earnings report also highlighted a pipeline of additional GLP‑1 candidates, including a newly released pill named Foundayo, which could further extend Lilly’s leadership in the obesity market.
In the near term, analysts will monitor the performance of Mounjaro and Zepbound, the progress of Lilly’s vaccine projects, and the company’s guidance for the remainder of 2026. Lilly’s next earnings call is scheduled for July 15, 2026, where it is expected to provide updated revenue forecasts and discuss the integration of the newly acquired vaccine assets.
Overall, Eli Lilly’s Q1 2026 results confirm the strength of its GLP‑1 portfolio while illustrating a strategic pivot toward infectious‑disease vaccines. The company’s current financial performance, coupled with its planned acquisitions, positions it to address both short‑term profitability and long‑term diversification.
